IGC Pharma reports FY25 EPS (9c) vs. (22c) last year

Reports revenue $1.2M vs. $1.3M last year. IGC Pharma (IGC) is strategically positioned for continued growth and innovation. Key objectives include: completing the CALMA Phase 2 trial; launching a second Phase 2 study to evaluate IGC-AD1’s potential disease-modifying effects; and deploying a beta version of MINT-AD, our AI-based diagnostic tool. We remain committed to creating long-term value for shareholders and accelerating breakthroughs that can change the lives of those affected by Alzheimer’s disease. “Fiscal Year 2025 stands as a testament to IGC Pharma’s unwavering commitment to addressing one of the most pressing global health challenges: Alzheimer’s disease,” said Ram Mukunda CEO of IGC Pharma. “We have not only advanced our lead asset, IGC-AD1, through critical clinical milestones but have also strategically expanded our reach and solidified our innovative position through AI integration and a growing pipeline. Our progress reflects the dedication of our team, the strength of our scientific foundation, and our relentless pursuit of meaningful solutions for patients and their families. IGC Pharma is not just developing therapies; we are building a future where Alzheimer’s is no longer an insurmountable challenge.”